Legis Daily

Drug Price Transparency in Medicaid Act of 2021

USA117th CongressHR-6101| House 
| Updated: 12/2/2021
Earl L. "Buddy" Carter

Earl L. "Buddy" Carter

Republican Representative

Georgia

Cosponsors (4)
Jerry L. Carl (Republican)Vicente Gonzalez (Democratic)Daniel Meuser (Republican)Chris Jacobs (Republican)

Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Drug Price Transparency in Medicaid Act of 2021 This bill requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with pharmacy benefit managers under Medicaid. The bill also extends funding for retail pharmacy surveys and requires additional information with respect to price concessions, dispensing fees, and survey participation to be made publicly available.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-5281
Drug Price Transparency in Medicaid Act of 2019
Dec 1, 2021
Introduced in House
Dec 1, 2021
Referred to the House Committee on Energy and Commerce.
Dec 2, 2021
Referred to the Subcommittee on Health.
  • Bill from Previous Congress

    HR 116-5281
    Drug Price Transparency in Medicaid Act of 2019


  • December 1, 2021
    Introduced in House


  • December 1, 2021
    Referred to the House Committee on Energy and Commerce.


  • December 2, 2021
    Referred to the Subcommittee on Health.

Health

Business recordsCongressional oversightGovernment information and archivesHealth care costs and insuranceHome and outpatient careInflation and pricesMedicaidPrescription drugsPublic contracts and procurementRetail and wholesale tradesState and local government operationsUser charges and fees

Drug Price Transparency in Medicaid Act of 2021

USA117th CongressHR-6101| House 
| Updated: 12/2/2021
Drug Price Transparency in Medicaid Act of 2021 This bill requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with pharmacy benefit managers under Medicaid. The bill also extends funding for retail pharmacy surveys and requires additional information with respect to price concessions, dispensing fees, and survey participation to be made publicly available.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-5281
Drug Price Transparency in Medicaid Act of 2019
Dec 1, 2021
Introduced in House
Dec 1, 2021
Referred to the House Committee on Energy and Commerce.
Dec 2, 2021
Referred to the Subcommittee on Health.
  • Bill from Previous Congress

    HR 116-5281
    Drug Price Transparency in Medicaid Act of 2019


  • December 1, 2021
    Introduced in House


  • December 1, 2021
    Referred to the House Committee on Energy and Commerce.


  • December 2, 2021
    Referred to the Subcommittee on Health.
Earl L. "Buddy" Carter

Earl L. "Buddy" Carter

Republican Representative

Georgia

Cosponsors (4)
Jerry L. Carl (Republican)Vicente Gonzalez (Democratic)Daniel Meuser (Republican)Chris Jacobs (Republican)

Health Subcommittee, Energy and Commerce Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Business recordsCongressional oversightGovernment information and archivesHealth care costs and insuranceHome and outpatient careInflation and pricesMedicaidPrescription drugsPublic contracts and procurementRetail and wholesale tradesState and local government operationsUser charges and fees